Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is increasingly being discussed, particularly when compared to past decades. The use of biologic agents has profoundly changed the history of this disease, as well as the management of psoriatic patients. Due to the enormous interest in psoriasis, as demonstrated within the scientific community and pharmaceuticals, new therapeutic targets have been identified and novel patented therapeutics are being tested. Areas covered: This review sought to give an overview of small molecules and antibodies patented in the last five years for the treatment of psoriasis. Therapeutic agents either in the early or advanced phase of development have been described, primarily based on a systematic search using the PubMed Medline database. Expert opinion: Though the recent introduction of new antipsoriatic agents has facilitated the management of long-term psoriasis, there is still a strong desire for alternative therapeutic options. Indeed, there remain unmet needs regarding safety and efficacy of psoriasis treatment that should be addressed. In this context, recently patented drugs may prove valid, interesting, and promising within the therapeutic paradigm.

Chiricozzi, A., Saraceno, R., Novelli, L., Fida, M., Caso, F., Scarpa, R., et al. (2016). Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015). EXPERT OPINION ON THERAPEUTIC PATENTS, 26(7), 757-766 [10.1080/13543776.2016.1192129].

Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015)

CHIRICOZZI, ANDREA;SARACENO, ROSITA;PERRICONE, ROBERTO;CHIMENTI, SERGIO;CHIMENTI, MARIA SOLE
2016

Abstract

Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is increasingly being discussed, particularly when compared to past decades. The use of biologic agents has profoundly changed the history of this disease, as well as the management of psoriatic patients. Due to the enormous interest in psoriasis, as demonstrated within the scientific community and pharmaceuticals, new therapeutic targets have been identified and novel patented therapeutics are being tested. Areas covered: This review sought to give an overview of small molecules and antibodies patented in the last five years for the treatment of psoriasis. Therapeutic agents either in the early or advanced phase of development have been described, primarily based on a systematic search using the PubMed Medline database. Expert opinion: Though the recent introduction of new antipsoriatic agents has facilitated the management of long-term psoriasis, there is still a strong desire for alternative therapeutic options. Indeed, there remain unmet needs regarding safety and efficacy of psoriasis treatment that should be addressed. In this context, recently patented drugs may prove valid, interesting, and promising within the therapeutic paradigm.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/16 - Reumatologia
English
Con Impact Factor ISI
biologic; JAK-STAT; pathogenesis; Psoriasis; small molecules; TNF-α; Drug Discovery3003 Pharmaceutical Science; Pharmacology
Chiricozzi, A., Saraceno, R., Novelli, L., Fida, M., Caso, F., Scarpa, R., et al. (2016). Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015). EXPERT OPINION ON THERAPEUTIC PATENTS, 26(7), 757-766 [10.1080/13543776.2016.1192129].
Chiricozzi, A; Saraceno, R; Novelli, L; Fida, M; Caso, F; Scarpa, R; Costa, L; Perricone, R; Romanelli, M; Chimenti, S; Chimenti, Ms
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/163891
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact